Adage Capital Partners Gp, L.L.C. Aveo Pharmaceuticals, Inc. Transaction History

Adage Capital Partners Gp, L.L.C.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$3.15 - $6.01 $4.73 Million - $9.02 Million	-1,500,000 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$5.12 - $6.89 $97,280 - $130,910	19,000 Added 1.28%	1,500,000 $9.27 Million
Q2 2021 Aug 16, 2021	BUY	$6.21 - $7.45 $3.21 Million - $3.85 Million	517,000 Added 53.63%	1,481,000 $9.76 Million
Q1 2021 May 17, 2021	BUY	$5.97 - $15.28 $5.76 Million - $14.7 Million	964,000 New	964,000 $7.06 Million

Ticker AVEO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 34,676,000
Description
AVEO Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing medicines for cancer patients. It markets its lead candidate, FOTIVDA, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC); and tivozanib for the ...

Get notified when there are updates to the investment portfolio of Adage Capital Partners Gp, L.L.C., based on Form 13F filings with the SEC.

Stay updated on Adage Capital Partners Gp, L.L.C. with notifications on news.